Jennison Associates
PHAT icon

Jennison Associates’s Phathom Pharmaceuticals PHAT Stock Holding History

Jennison Associates’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,042,325
Closed -$44.2M – 623
2025
Q1 		$44.2M Sell
7,042,325
-20,182
-0.3% -$123K 0.03% 231
2024
Q4 		$57.3M Buy
7,062,507
+1,196,118
+20% +$14.8M 0.03% 210
2024
Q3 		$106M Buy
5,866,389
+3,108,810
+113% +$43.5M 0.07% 132
2024
Q2 		$28.4M Buy
2,757,579
+1,109,882
+67% +$11.4M 0.02% 295
2024
Q1 		$17.5M Buy
+1,647,697
New +$14M 0.01% 353

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $653B AUM 32.41% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.08B AUM 85.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return